CD274 and nasopharyngeal carcinoma: 27 patients who have received treatment previously being diagnosed with, PD-L1 positive, metastatic or recurrent nasopharyngeal carcinoma were treated with pembrolizumab (10 mg/kg every 2 weeks for up to two years).